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1. Introduction
  Trichomonas vaginalis (T. vaginalis), a flagellated 
protozoon with worldwide distribution, is a causative 
agent of human trichomoniasis. According to WHO, over 
170 million people are infected with T. vaginalis annually 
worldwide[1]. The parasite generally infects the squamous 
epithelium of the genital tract, but sporadically it is 
recovered from the urethra, fallopian tubes and pelvis[2]. 
The incubation period is varies between 4 to 28 days in 
infected individuals[3]. The main clinical picture in acute 
infection includes vaginatis, cervicitis and urethritis in 
women and prostatitis and other genito-urinary syndromes 
in men. Other complications associated with trichomoniasis 
are adnexitis, pyosalpinx, and endometritis; infertility and 
low birth weight; and cervical erosion[4]. The prevalence and 
spectrum of disease in males are less well characterized; 
the infection appears to usually be asymptomatic but 
occasionally causes urethritis and prostatitis[5-7]. Since 
probably almost 50% of trichomonal infections are 
asymptomatic, the infection can spread easily. Another 
serious aspect of trichomoniasis is the association between 
T. vaginalis infection and an increased risk of transmission 
of other sexually transmitted diseases, including human 
immunodeficiency virus[8,9]. 
  Despite high prevalence and associated risk of 
trichomoniasis, very little is known about the biological 
variability of the parasite. Infected individuals show a 
great variability in the pathological manifestations, from 
asymptomatic presentation to increased risk of pelvic 
inflammatory disease and tubal infertility[10]. The reasons 
for such variation and how the characteristics of every 
isolate impact the clinical manifestations of trichomoniasis 
are not well known. Experimental drug susceptibility 
testing is one of the parameter that can be applied to the 
characterization of isolates. Assays of variability have been 
used by various researchers in “standard” strains or clinical 
isolates without exact definition of their drug susceptibility 
differences[11,12]. However, ours is first of an attempt in 
clonal stocks. Establishment of long term clonal lines helps 
to determine the actual range of susceptibility of different 
parasite lines to a particular drug. These well defined 
sensitive and resistant lines can then be used as a reference 
against which field isolates can be compared. This allows 
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a correlation of the in vitro sensitivity of the reference lines 
with the clinical outcome. 
  Metronidazole (MTZ) and a related 5-nitroimidazole 
drug, tinidazole (TNZ), are the treatment of choice for 
trichomoniasis. Satranidazole (STZ) is one of a large series 
of nitroimidazoles with a potent antiprotozoal activity. 
Nitazoxanide (NTZ) is a new thiazolide antiparasitic agent 
that shows excellent in vitro activity against a wide variety 
of protozoa and helminths[13]. Since the introduction of 
5-nitroimidazoles in the 1960s, there have been reports of 
increases in the prevalence of metronidazole-resistant T. 
vaginalis infection[14]. So, it is of great interest to study the 
susceptibility these drugs to clonal strains of T. vaginalis. 
  The aim of the present study was to produce comparative 
data on a group of T. vaginalis clonal strains with varied 
drug responses using identical methods and materials. We 
also tried to correlate the growth rate of strains with the 
relative susceptibility to drugs in vitro.
2. Materials and methods
2.1. Strains of T. vaginalis
  A local strain of T. vaginalis employed for this study was 
kindly provided by Professor Nancy Malla from Postgraduate 
Institute of Medical Education and Research  (PGIMER), 
Chandigarh, India. 
  The clonal strains investigated in this study had been 
isolated using the method by Samuels[15] with certain 
modifications. Briefly, stock trichomonads for plating were 
cultured in TYI-S-33 medium. Hemocytometer counts 
were made with 48 h old culture of trichomonads and the 
organisms serially diluted with TYI-S-33 medium to the 
numbers desired, usually 30-50 per 0.5 mL. First base layer 
of 20 mL of 1.6% agar in Trichomonads modified CPLM base 
medium (Himedia lab, Mumbai) were poured from 20- or 
25-mm tubes into sterile glass Petri dishes. Just before 
pouring, 0.2 mL of a common solution of 10 000 units/mL of 
penicillin and streptomycin (PAA lab, Austria) was added 
to each tube and mixed by gentle swirling. Immediately 
after pouring, the plates were placed in incubator at 37 曟 
and 5% CO2 to harden for at least 30 min after the last was 
poured. Overlay medium with 0.8% agar, 10 mL per 20 or 25 
mm tube, was melted and cooled in a water bath to 40 曟. 
Warmed penicillin-streptomycin mixture (0.1 mL) and 1ml 
of heat inactivated adult bovine serum (PAA lab, Austria) 
were added, then the diluted organisms in 0.5 mL of TYI-
S-33 medium at room temperature. Mixing and pouring 
of the overlay was done as rapidly as possible to reduce 
temperature shock. The plates were again set in incubator 
at 37 曟 and 5% CO2 for 3-5 days. The colony embedded in 
agar containing organisms was transferred to 0.5 mL of TYI-
S-33 medium in a sterile 15 mL glass tube using a platinum 
wire, flattened in the plane of a lance-shaped loop. After 
release of the organisms, TYI-S-33 medium was added to 
a total volume of 10 mL. Five clonal strains T. vaginalis 
namely C1, C2, C3, C4, C5 were isolated. T. vaginalis(TV) 
strain  from PGIMER Chandigarh was used as reference for 
drug susceptibility testing.
2.2. Culture medium
  All strains were cultured axenically and maintained in pre-
warmed TYI-S-33 medium containing 10% bovine serum in 
15 mL glass tubes at 37 曟 in an atmosphere containing 5% 
CO2. Subcultures were usually done every 2-3 days.
2.3. Growth assay in 96 well microtitre plate
  The numbers of trichomonads per mL in 24 h old culture 
of all the strains employed in study were determined using 
a hemocytometer chamber. The strains were then diluted 
using TYI-S-33 medium to give final concentration of 5伊104 
trichomonads/mL and 200 毺L aliquots of each were then 
introduced in to microtitre plates with 96 flat-bottomed 
wells (CELLSTAR®, greiner bio-one). Microtitre plates were 
then incubated at 37 曟 in an atmosphere containing 5% CO2 
(Heraeus instruments). Samples were taken for counting 
after mechanical vortexing for 5 s to 10 s, using long tipped 
Pasteur pipettes. The microtitre plates were tightly capped 
and opened only for sampling. Only motile trichomonads 
were counted using hemocytometer under inverted 
microscope (Nikon, ECLIPSE TE300). The trichomonads 
counts for growth study were made at 24 h interval for total 
of 120 h.  Each experiment was performed in duplicate, with 
duplicate counts made for each sample. Generation time 
and number of generations calculated using the formula 
Generation time tg = t/n
 n=
lgb-lga
0.3010
Where, b = No. of cells in population
             a = No. of cells in initial innoculum
           n = No. of generations that occured between time of 
inoculation to time of sampling
2.4. Drug preparation
  Metronidazole (MTZ) (J.B.Pharmaceuticals, Mumbai), 
Tinidazole (TNZ) (Zydus Alidac, Ahmedabad), Satranidazole 
(STZ) (Ciba Geigy Limited, Mumbai) and Nitazoxanide 
(NTZ) (Ind-Swift lab, Chandigarh) were used. MTZ and TNZ 
were dissolved in sterile distilled water. STZ and NTZ were 
dissolved in DMSO. Drug solutions were freshly prepared 
before use by diluting with TYI-S-33 medium to appropriate 
concentration.
2.5. Drug susceptibility testing
  Standard microtitre plates with 96 flat-bottomed wells 
(CELLSTAR®, greiner bio-one) were used in the test. Drugs 
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of various concentrations (from 0.048 to 200 毺M) were 
added to the wells in 50 毺L aliquots. A 200 毺L suspension 
containing 1伊104 T. vaginalis was then placed into each 
well[16]. All the drug and control studies were carried out in 
duplicate; a minimum of two independent experiments was 
conducted for each drug tested. The plates were incubated 
at 37 曟 and were examined after 48 h with an inverted 
microscope (Nikon, ECLIPSE TE300) at 40伊 for motile 
trichomonads. The minimal inhibition concentration (MIC) is 
defined as the lowest drug concentration in which no motile 
organism was seen. Effect of DMSO on the parasite was 
investigated and observed that 2% (v/v) concentration had 
no effect on parasite motility.
3. Results 
3.1. Growth curve
  The growth curves of the five clonal strains and one 
reference strain are presented in Figure 1. 
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Figure 1. Growth curves of six strains of T. vaginalis on TYI-S-33 
medium. 
48 hr old culture of T. vaginalis that had not entered the stationary 
phase was used for growth study and drug susceptibility testing. Final 
concentration of innoculum was 5伊104 trichomonads /mL. All the 
values were expressed as Mean依SEM.
  The approximate doubling time of these clonal isolates was 
13 to 14 h, and they reached the stationary phase of growth 
after about 72 h. Exponential growth occurred well beyond 
48 h, resulting in maximum concentrations of organisms per 
mL observed. In contrast after 96 h 99% of the cultures were 
non-motile and presumed dead. The growth curve indicates 
that TV and C2 were the fastest and C1 and C5 were slowest 
growing strains. The growth rate of C3 and C4 falls between 
those of the other four. The generation time found for TV and 
C2 strains were 13 h 21 min; 14 h 11 min for C1 and C3; 13 h 
45 minutes for C4; 14 h 27 min for C5.
3.2. Drug susceptibility testing
  The in vitro drug susceptibility of five clonal strains tested 
is summarised in Table 1.
  All clonal strains showed an inhibited growth in vitro after 
an incubation period of 48 hours with 6.4 to 25 毺m of  MTZ. 
Concentrations of TNZ ranging from 0.8 to 12.5 毺m were 
lethal in all the strains tested. MIC values of STZ showed 
variation between 3.2 to 12.5 毺m. Clonal strains C1 and C5 
were the least sensitive to MTZ, TNZ and STZ. The response 
of clonal strain C2 was similar to that of reference strain. 
The sensitivity of clonal strain C3 and C4 were similar to 
all the drug tested except TNZ (C3= 6.4 毺m; C4=3.2 毺m). 
Surprisingly, no difference in NTZ sensitivity found between 
the clonal strains tested and a reference strain.
4. Discussion
  Assays of variability in T. vaginalis have been used 
by various researchers in “standard” strains or clinical 
isolates without exact definition of their drug susceptibility 
differences[11,12]. However, ours is first of an attempt in 
clonal stocks.
  There can be no doubt that T. vaginalis contains a number 
of strains which vary in their susceptibility to same drug. 
The degree of drug susceptibility can be affected by 
environmental conditions. A comparison of the relative drug 
susceptibility of various strains under different but uniform 
set of conditions always shows differences. One of the 
inherent factors which seem to affect the drug susceptibility 
is the rate of multiplication of the parasites in the culture 
media. In our study, the variability of growth kinetic of 
T. vaginalis was observed in 96 well plates. The use of 
multiwell plates, thus removing the tedium and unreliable 
reproducibility of tube assays[11]. The growth curves and 
generation times of the five clonal strains are compared 
with parent strain. It is evident that among the strains of 
T. vaginalis there is a good correlation between rates of 
growth with the relative susceptibility of the strains to drugs 
in vitro. On the other hand, it appears that the more drug-
susceptible the strains of T. vaginalis, the shorter their 
generation time. In reference to the clonal strains of T. 
vaginalis the rates of growth in culture reflects their drug 
susceptibility. The effect of a new thiazolide antiparasitic 
agent NTZ did not differ between the slow and fast growing 
Table 1
Susceptibility of T.vaginalis clonal strains to MTZ, TNZ, STZ and NTZ 
in comparison to reference strain (TV) (毺m).  
Strain
MIC
MTZ TNZ STZ NTZ
TV   6.4   0.8   3.2 12.5
C1 25.0 12.5 12.5 12.5
C2   6.4   0.8   3.2 12.5
C3 12.5   6.4   6.4 12.5
C4 12.5   3.2   6.4 12.5
C5 25.0   6.4 12.5 12.5
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strain. This suggests that the probable mode of action of 
NTZ is different from that of 5-nitroimidazoles. NTZ was 2 
times as active as MTZ against C1 and C5 (less susceptible to 
MTZ) and nearly similar activity against susceptible strains. 
Higher the activity than MTZ seen for NTZ in relatively MTZ- 
refractory strains (C1 and C5) of T. vaginalis indicates that 
resistance mechanism to MTZ may be to a variable extent 
bypassed by NTZ. In view of NTZ unique mechanism of 
action, should be considered for further clinical evaluation 
in the treatment of MTZ resistance T. vaginalis. However, 
additional data to support this context are required.  
  Results of our study show that there was a striking 
difference in the activity of 5- nitroimidazoles against clonal 
strains. MIC of MTZ differed 2-4 fold between clonal strains. 
C1 and C5 exhibited a decreased susceptibility to two other 
antitrichomonad nitroimidazoles, i.e., TNZ and STZ. The 
reported similarity in the mechanism of action of MTZ, TNZ 
and STZ has been confirmed in C1 and C5 showed a markedly 
decreased susceptibility to all three compounds. For all 
clonal strains, the MIC for TNZ was lower than that for MTZ, 
but it was evident that those clonal strains less susceptible 
to MTZ have decreased sensitivity to TNZ. This finding is not 
surprising, as both compounds are 5-nitroimidazoles.
  In conclusion, this is the first description of biological 
variability in clonal stock of T. vaginalis. It is evident 
that among the clonal strains of T. vaginalis there is 
good correlation between rates of growth with the relative 
susceptibility of the strains in vitro. C1 and C5 were found 
to be less susceptible to 5- nitroimidazoles and NTZ had 
shown similar activity against all the strains tested. Further 
studies will be necessary to ascertain the importance of this 
variability in clinical infection.
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